Ziprasidone HCl monohydrate

产品说明书

Print
Chemical Structure| 138982-67-9 同义名 : 盐酸齐拉西酮水合物;齐拉西酮盐酸盐一水合物 ;CP-88,059; Ziprasidone (hydrochloride hydrate); CP 88059 hydrochloride monohydrate; Ziprasidone hydrochloride monohydrate
CAS号 : 138982-67-9
货号 : A473367
分子式 : C21H24Cl2N4O2S
纯度 : 97%
分子量 : 467.41
MDL号 : MFCD00921885
存储条件:

Pure form Inert atmosphere, room temperature

In solvent -20°C:3-6个月-80°C:12个月

溶解度 :

DMSO: 25 mg/mL(53.49 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

生物活性
描述 Ziprasidone HCl H2O is a full antagonist of D2 receptors and of 5-HT2A receptors and is a partial agonist of 5-HT1A receptors, of 5-HT2C receptors and 5-HT1D receptors, used as an atypical antipsychoticfor the treatment of schizophrenia as well as acute mania and mixed states associated with bipolar disorder. Ziprasidone HCl has high affinity for rat (Ki: 3.4 nM)/human (2.5 nM) 5-HT1A receptors, 5-HT2A (0.42 nM), and dopamine D2 receptors (4.8 nM). Ziprasidone HCl is an inhibitor of norepinephrine reuptake[2]. In vivo, ziprasidone antagonizes 5-HT2A receptor-induced head twitch with 6-fold higher potency than for blockade of d-amphetamine-induced hyperactivity, a measure of central dopamine D2 receptor antagonism. The compound is well tolerated in animals at doses producing effective dopamine antagonism in the brain[3]. Ziprasidone exhibits dose proportional, linear changes in exposure and is hepatically metabolized primarily by aldehyde oxidase[4]. Short-term treatment with intramuscular ziprasidone was effective and well tolerated in patients with acute agitation associated with psychosis[5].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT01185743 Schizophrenia ... 展开 >> Diabetes 收起 << Phase 4 Completed - Austria ... 展开 >> Medical University of Vienna Vienna, Austria, 1090 收起 <<
NCT00538629 - Completed - -
NCT01598324 - Terminated(Clinical trial from... 展开 >> which subjects were recruited closed to enrollment) 收起 << - United States, Massachusetts ... 展开 >> McLean Hospital - McLean Imaging Center Belmont, Massachusetts, United States, 02478 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.14mL

0.43mL

0.21mL

10.70mL

2.14mL

1.07mL

21.39mL

4.28mL

2.14mL

参考文献

[1]Ravikiran A, Arthanareeswari M, et al. Nonisothermal kinetics analysis of the dehydration of ziprasidone hydrochloride monohydrate by thermogravimetry. Indian J Pharm Sci. 2013 May;75(3):361-4.

[2]Rollema H, Lu Y, Schmidt AW, Sprouse JS, Zorn SH. 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol Psychiatry. 2000 Aug 1;48(3):229-37

[3]Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe JA 3rd, et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther. 1995 Oct;275(1):101-13

[4]Patel NC, Keck PE Jr. Ziprasidone: efficacy and safety in patients with bipolar disorder. Expert Rev Neurother. 2006 Aug;6(8):1129-38

[5]Gunasekara NS, Spencer CM, Keating GM. Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2002;62(8):1217-51